/GENB

GENB

GENB

$15.72USD↑+2.14%+0.33 today

MARKET CAP

2.0B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$15 – $16

52W RANGE

$11

$23

AI Summary

Stalk

StalkMedium

GENB remains in a broader bullish context with price holding above its medium- and long-term moving averages. Recent price has pulled back into the converging 9-, 20-, and 50-day EMAs, presenting a potential entry zone upon clear acceptance. RSI is neutral, and no exhaustion signals are visible, but a decisive break below the 50-day would negate the bullish setup. Patience is advised until pullback into the EMAs is absorbed, confirming support before committing.

↑Cash position of $457.4M supports runway into H1 2028.
↑GB-0895 Phase 3 asthma trial holds FDA Fast Track designation.
↓Q2 collaboration revenue fell to $6.3M from $10.1M YOY.

Full analysis →

Buying

2

institutions

Selling

4

institutions

New Positions

2

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
BI Blackrock, Inc. Q2 2026	BUYNEW	1.66 M	28.00 M	+1.66 M	+0.0%	0.00%
JC Jpmorgan Chase & Co Q2 2026	SELL	1.41 M	23.84 M	+-1.54 M	-29.7%	0.00%
RT Renaissance Technologies LLC Q2 2026	BUYNEW	39.69 K	669.49 K	+39.69 K	+0.0%	0.00%
MM Millennium Management LLC Q2 2026	SELL	21.93 K	369.89 K	+-354.97 K	-92.2%	0.00%
BA Balyasny Asset Management L.P. Q2 2026	SELL	0.00	0.00	+-79.49 K	-100.0%	0.00%
BH Brevan Howard Capital Management LP Q2 2026	SELL	0.00	0.00	+-12.57 K	-100.0%	0.00%